Efficacy and safety of deflazacort in diabetic subjects infected with SARS-CoV-2
Deflazacort demonstrated a lower incidence of hospital admission for glycaemic decompensation compared to standard treatment with dexamethasone/methylprednisolone in SARS-CoV-2 positive outpatients. There were no differences in COVID-19-related hospitalizations between the two groups.
Authors
- Alessandro Di Gasbarro
- Claudio Ucciferri (ORCID: https://orcid.org/0000-0002-5866-3849)
- Katia Falasca (ORCID: https://orcid.org/0000-0002-8795-5410)
- Jacopo Vecchiet (ORCID: https://orcid.org/0000-0001-9250-4844)
Institutions
- University of Chieti-Pescara (IT)
Publication Details
- Journal
- Multidisciplinary Respiratory Medicine
- Published
- 2025-10-03
- DOI
- https://doi.org/10.5826/mrm.2025.1035
- Citations
- 2
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.79